User: Guest  Login
More Searchfields
Simple search
Title:

Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile.

Document type:
Journal Article
Author(s):
Reidel, Veronika; Kauschinger, Johanna; Hauch, Richard T; Müller-Thomas, Catharina; Nadarajah, Niroshan; Burgkart, Rainer; Schmidt, Burkhard; Hempel, Dirk; Jacob, Anne; Slotta-Huspenina, Julia; Höckendorf, Ulrike; Peschel, Christian; Kern, Wolfgang; Haferlach, Torsten; Götze, Katharina S; Jilg, Stefanie; Jost, Philipp J
Abstract:
Somatic mutations in genes such as , , or adversely affect the outcome of patients with myelodysplastic syndromes (MDS). Since selective BCL-2 inhibition is a promising treatment strategy in hematologic malignancies, we tested the therapeutic impact of ABT-199 on MDS patient samples bearing an adverse mutational profile. By gene expression, we found that the level of pro-apoptotic BIM significantly decreased during MDS disease progression in line with an acquired resistance to cell death. Supp...     »
Journal title abbreviation:
Oncotarget
Year:
2018
Journal volume:
9
Journal issue:
25
Pages contribution:
17270-17281
Language:
eng
Fulltext / DOI:
doi:10.18632/oncotarget.24775
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/29707107
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie); Institut für Allgemeine Pathologie und Pathologische Anatomie; Klinik und Poliklinik für Orthopädie und Sportorthopädie
 BibTeX